Our Contribution to the Clinical Research of HAE

  • Human pasteurized C-1 esteraze inhibitor concentrate in subject with congenital C1-INH deficiency and acute abdominal ar facial HAE attacks. (CE1145). 2006-2007
  • A randomized, placebo controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema (C1 1304-01). 2007.
  • An Open-label exploratory Phase II study of the safety and Prophylactic Effect of a weekly 50 U/kg rC1INH treatment in Asymptomatic patients with hereditary C1INH deficiency (HAE).(OPERA)(C1 1207). 2009-2010
  • Development and Trans-cultural Validation of an International Specific Questionnaire (IHAE-QoL) for Assessment of Health Related Quality of Life in Adult Patients with Hereditary Angioedema due to C1 inhibitor Deficiency (HAE) and Quality of Life Study (DTV-IHAE-QoL). 2008-2010.

Last update: 08.25.2009